Rapid antibody development yields possible treatment for yellow fever
The experimental drug has shown promise in early-stage clinical trials conducted in Singapore.
![“The biology [around gut bacteria’s influence on health] is fairly complex, and we’re still in the early days of unravelling it, but there have been a number of clinical studies that have reported benefits to restoring gut health, and that’s our north star: the clinical data,” Finch co-founder and Chief Executive Officer Mark Smith PhD ’14 says.](/sites/default/files/styles/term_page__news_article/public/images/202007/MIT-Finch-01.jpg?itok=-8olXqg-)
Finch Therapeutics unleashes the power of the gut
The company is developing treatments that restore gut bacteria in people struggling with a range of diseases.
How cancer drugs find their targets
Certain cancer therapeutics concentrate within cells — a finding that could change the way scientists think about drug design.
Experimental peptide targets Covid-19
Computational modeling yields a protein fragment that could bind to coronavirus spike proteins and destroy them.
Study finds path for addressing Alzheimer’s blood-brain barrier impairment
MIT researchers pinpoint mechanism and demonstrate that drugs could help.
New technology enables fast protein synthesis
Automated tabletop machine could accelerate the development of novel drugs to treat cancer and other diseases.
How often do vaccine trials hit paydirt?
Study: Vaccines find more success in development than any other kind of drug, but have been relatively neglected in recent decades.
Study analyzes contamination in drug manufacturing plants
Report offers guidelines to help prevent viruses from tainting biopharmaceutical drugs.
New model of the GI tract could speed drug development
Studies of drug absorption in the small intestine could help researchers identify medicines that can be taken orally.
Jim Collins receives funding to harness AI for drug discovery
The Audacious Project commitment will support the development of new classes of antibiotics to treat the world’s deadliest bacterial pathogens.
Professor Emeritus Arnold Demain, a pioneer in the development of antibiotics, dies at 92
An eminent microbiologist, Demain conducted groundbreaking antibiotics research and mentored hundreds of young scientists.
An experimental peptide could block Covid-19
MIT chemists are testing a protein fragment that may inhibit coronaviruses’ ability to enter human lung cells.
Genetic screen offers new drug targets for Huntington’s disease
Neuroscientists identify genes that modulate the disease’s toxic effects.
The new front against antibiotic resistance
Deborah Hung shares research strategies to combat tuberculosis as part of the Department of Biology's IAP seminar series on microbes in health and disease.
MIT School of Engineering and Takeda join to advance research in artificial intelligence and health
A key part of J-Clinic, the MIT-Takeda Program will create educational opportunities and support cutting-edge research to positively impact human health.